PharmaEssentia Wins US, Japan Approvals for Ropeg to Treat Essential Thrombocythemia

PharmaEssentia secured US and Japanese approvals in August for BESREMi (ropeginterferon alfa-2b) to treat essential thrombocythemia. BESREMi is the only FDA-approved drug for both essential thrombocythemia and polycythemia vera. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaEssentia Corporation published the original content used to generate this news brief via (Ref. ID: 202610160801BIZWIRE_USPR_____20261016_BW990975) on October 16, 2026, and is solely responsible for the information contained therein. (C)